Products Related to Gene-ID: 10288

FAB3832P) and either (A) Mouse Anti-Human LILRB2/CD85d/ILT4 Monoclonal Antibody (Catalog # MAB2078) or (B) Mouse IgG_2AIsotype Control (Catalog # MAB003) followed by Allophycocyanin-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # F0101B)." class="big_lightbox"> FAB3832P) and either (A) Mouse Anti-Human LILRB2/CD85d/ILT4 Monoclonal Antibody (Catalog # MAB2078) or (B) Mouse IgG_2AIsotype Control (Catalog # MAB003) followed by Allophycocyanin-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # F0101B)." alt="Human peripheral blood monocytes were stained with Mouse Anti-Human CD14 PE-conjugated Monoclonal Antibody (Catalog # FAB3832P) and either (A) Mouse Anti-Human LILRB2/CD85d/ILT4 Monoclonal Antibody (Catalog # MAB2078) or (B) Mouse IgG_2AIsotype Control (Catalog # MAB003) followed by Allophycocyanin-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # F0101B)." class="big_thumb" />

2078-T4), immobilized onto a microplate, supports the adhesion of the HSB2 human peripheral blood acute lymphoblastic leukemia cell line in a dose-dependent manner (orange line). Adhesion elicited by Recombinant Human LILRB2/CD85d/ILT4 Fc Chimera (35 µg/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human LILRB2/CD85d/ILT4 Monoclonal Antibody (Catalog # MAB2078). The ND₅₀ is typically 0.2-0.8 µg/mL." class="big_lightbox"> 2078-T4), immobilized onto a microplate, supports the adhesion of the HSB2 human peripheral blood acute lymphoblastic leukemia cell line in a dose-dependent manner (orange line). Adhesion elicited by Recombinant Human LILRB2/CD85d/ILT4 Fc Chimera (35 µg/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human LILRB2/CD85d/ILT4 Monoclonal Antibody (Catalog # MAB2078). The ND₅₀ is typically 0.2-0.8 µg/mL." class="big_thumb" />

2078-T4), immobilized onto a microplate, supports the adhesion of the HSB2 human peripheral blood acute lymphoblastic leukemia cell line in a dose-dependent manner (orange line). Adhesion elicited by Recombinant Human LILRB2/CD85d/ILT4 Fc Chimera (35 µg/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human LILRB2/CD85d/ILT4 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF2078). The ND₅₀ is typically 0.3-1.0 µg/mL." class="big_lightbox"> 2078-T4), immobilized onto a microplate, supports the adhesion of the HSB2 human peripheral blood acute lymphoblastic leukemia cell line in a dose-dependent manner (orange line). Adhesion elicited by Recombinant Human LILRB2/CD85d/ILT4 Fc Chimera (35 µg/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human LILRB2/CD85d/ILT4 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF2078). The ND₅₀ is typically 0.3-1.0 µg/mL." alt="Recombinant Human LILRB2/CD85d/ILT4 Fc Chimera (2078-T4), immobilized onto a microplate, supports the adhesion of the HSB2 human peripheral blood acute lymphoblastic leukemia cell line in a dose-dependent manner (orange line). Adhesion elicited by Recombinant Human LILRB2/CD85d/ILT4 Fc Chimera (35 µg/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human LILRB2/CD85d/ILT4 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF2078). The ND₅₀ is typically 0.3-1.0 µg/mL." class="big_thumb" />

VC004). Before incubation with the primary antibody, tissue was subjected to heat-induced epitope retrieval using VisUCyte Antigen Retrieval Reagent-Basic (Catalog # VCTS021). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to cell surface. View our protocol for IHC Staining with VisUCyte HRP Polymer Detection Reagents." class="big_lightbox"> VC004). Before incubation with the primary antibody, tissue was subjected to heat-induced epitope retrieval using VisUCyte Antigen Retrieval Reagent-Basic (Catalog # VCTS021). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to cell surface. View our protocol for IHC Staining with VisUCyte HRP Polymer Detection Reagents." class="big_thumb" />

FAB3832P) and either (A) Mouse Anti-Human LILRB2/CD85d/ILT4 Monoclonal Antibody (Catalog # MAB2078R) or (B) Mouse IgG2A Isotype Control (Catalog # MAB003) followed by Allophycocyanin-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # F0101B). View our protocol for Staining Membrane-associated Proteins." class="big_lightbox"> FAB3832P) and either (A) Mouse Anti-Human LILRB2/CD85d/ILT4 Monoclonal Antibody (Catalog # MAB2078R) or (B) Mouse IgG2A Isotype Control (Catalog # MAB003) followed by Allophycocyanin-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # F0101B). View our protocol for Staining Membrane-associated Proteins." alt="Human peripheral blood monocytes were stained with Mouse Anti-Human CD14 PE-conjugated Monoclonal Antibody (Catalog # FAB3832P) and either (A) Mouse Anti-Human LILRB2/CD85d/ILT4 Monoclonal Antibody (Catalog # MAB2078R) or (B) Mouse IgG2A Isotype Control (Catalog # MAB003) followed by Allophycocyanin-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # F0101B). View our protocol for Staining Membrane-associated Proteins." class="big_thumb" />

2078-T4), immobilized onto a microplate, supports the adhesion of the HSB2 human peripheral blood acute lymphoblastic leukemia cell line in a dose-dependent manner (orange line) as measured by Calcein AM. Adhesion elicited by Recombinant Human LILRB2/CD85d/ILT4 Fc Chimera (35 µg/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human LILRB2/CD85d/ILT4 Monoclonal Antibody (Catalog # MAB2078R). The ND₅₀ is typically0.15-0.9 µg/mL." class="big_lightbox"> 2078-T4), immobilized onto a microplate, supports the adhesion of the HSB2 human peripheral blood acute lymphoblastic leukemia cell line in a dose-dependent manner (orange line) as measured by Calcein AM. Adhesion elicited by Recombinant Human LILRB2/CD85d/ILT4 Fc Chimera (35 µg/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human LILRB2/CD85d/ILT4 Monoclonal Antibody (Catalog # MAB2078R). The ND₅₀ is typically0.15-0.9 µg/mL." class="big_thumb" />

914-AN) binds with a typical ED₅₀ of 25-150 ng/mL." class="big_lightbox"> 914-AN) binds with a typical ED₅₀ of 25-150 ng/mL." alt="When Recombinant Human LILRB2/CD85d/ILT4 (Catalog # 8429-T4) is coated onto a microplate at 2 µg/mL, Recombinant Human Angiopoietin-like 7 Protein (Catalog # 914-AN) binds with a typical ED₅₀ of 25-150 ng/mL." class="big_thumb" />

9795-AN) is immobilized at 1 µg/mL (100 µL/well), Biotinylated Recombinant Human LILRB2/CD85d/ILT4 Fc Chimera Avi-tag (Catalog # AVI2078) binds with an ED₅₀ of 10-80 ng/mL." class="big_lightbox"> 9795-AN) is immobilized at 1 µg/mL (100 µL/well), Biotinylated Recombinant Human LILRB2/CD85d/ILT4 Fc Chimera Avi-tag (Catalog # AVI2078) binds with an ED₅₀ of 10-80 ng/mL." alt="When Recombinant Human Angiopoietin‑like Protein 2/ANGPTL2 C-Terminal Fragment (9795-AN) is immobilized at 1 µg/mL (100 µL/well), Biotinylated Recombinant Human LILRB2/CD85d/ILT4 Fc Chimera Avi-tag (Catalog # AVI2078) binds with an ED₅₀ of 10-80 ng/mL." class="big_thumb" />

CP004) at 2 μg/mL (100 µL/well), the concentration of Recombinant Human Angiopoietin-like 7 Protein (914-AN) that produces 50% of the optimal binding response is 0.100-0.800 μg/mL." class="big_lightbox"> CP004) at 2 μg/mL (100 µL/well), the concentration of Recombinant Human Angiopoietin-like 7 Protein (914-AN) that produces 50% of the optimal binding response is 0.100-0.800 μg/mL." alt="When Biotinylated Recombinant Human LILRB2/CD85d/ILT4 His-tag Avi-tag (Catalog # AVI8429) is captured on EvenCoat Streptavidin Coated Plates (CP004) at 2 μg/mL (100 µL/well), the concentration of Recombinant Human Angiopoietin-like 7 Protein (914-AN) that produces 50% of the optimal binding response is 0.100-0.800 μg/mL." class="big_thumb" />